ETOSAID
Manufacturer Details
MACLEODS
Compositions:
Etoricoxib 60mg/90mg/120mg f.c. tablets,
|
Strength
|
Rate
|
Packing Style
|
|
60mg f.c.
|
64.90
|
10s f.c. tablets
|
|
90mg f.c.
|
96.80
|
10s f.c. tablets
|
|
120mg f.c.
|
92.50
|
10s f.c. tablets
|
List of Related Indications:
List Of Drugs:
- Etoricoxib - Selective Cox 2- Inhibitors- (FDC- List ) -(Mar 2008)
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
With coumarins, anticoagulant effect possibly enhanced .
Plasma concentrations of erthinyloestradiol increased when given concomitantly
Plasma concentration of etoricoxib reduced when given with rifampicin.
Patients receiving digoxin concomittantly with etoricoxib should be monitored closely because the
risk of digoxin toxicity
May increase concentration of methotrexate.
May also have the general drug interactions of NSAIDs
Indication:
U.S FDA APPROVED DRUGS FROM 01-01-08 TO 31-12-08
Drug name Indication Date of Approval
98. Etoricoxib injection 90mg/ml 28-03-08
For short term ue in acute painful condition in
adult only
202. Etoricoxib roll on Topical solution 1%v/v
For the treatment of pain,swelling & inflammatory
conditions due to arthiritis
211. Etoricoxib 30-09-08
+ PCM (60mg + 500mg) tablets
For the short term use of acute painful and inflammatory
conditions
Rhematoid arthiritis Osteoarthiritis
U.S FDA APPROVED DRUGS DURING 2004
192. Etoricoxib 05-03-2004
NSAID
U.S,FDA APPROVED DRUGS DURING 2006
159. Etoricoxib 10mg + 14-12-2006
Methyl salicylate 100mg +
Menthol 50mg +
Linseed oil 30mg/gm of Gel Acute Musculoskeletal pain
U.S.FDA APPROVED DRUGS DURING 2007
41. Etoricoxib 10mg + 21-03-07
Methyl salicylate 20mg per gm of cream
Acute musculoskeletal pain
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Etoricoxib NSAID 05-03-2004
2. Etoricoxib + PCM (60mg +50mg) 30-09-2008
Tablets
For short term use in acute painful and inflammatory condition
3. Etoricoxib 1% + Menthol 5% spray 16-03-2010
For the topical treatment of acute Musculoskeletal pain
4. Eoricoxib 10mg +Methyl salicylate 100mg + 14-12-2006
Menthol 50mg + Linseed oil 30mg/gm of gel
5. Etoricoxib 10mg + Methyl Salicylate 21-03-2007
20mg per gm of ctream
Acute Musculoskeletal pain
6. Etoricoxib Injection 28-03-2008
90mg/ml
For short term use in acute painful condition in adults
7. Etoricoxib Roll on Topical 16-09-2008
Solution 1% v/v
For the treatment of pain, swelling, & inflammatory conditions
due to arthiritis
Adverse Reaction:
Headache, diarrheoa, nausea
Upper respiratory tract infection
Increasedcrisk of thrombotic events.
Dizziness, fatigue, insomnia.
Occasional fecal blood loss.small increases in blood pressure.
Contra-Indications:
Previous hypersentivity to the drug, acute peptic ulcer disease or GI bleeding.
Severe renal or hepatic dysfunction.
Patients with a history of hypersentivity to aspirin or other non-steroidal anti-infammatory drugs
Special precautions-
History of allergy, conditions predisposing to gastrointestinal events.
Patients with hypertension,angina, myocardial infarction, other cardiovascular diseases.
mild to moderate liver disease ,mild to moderate renal impairment.
Pregnancy and lactation.
Dosages/ Overdosage Etc:
Rhematoid arthiritis
Osteoarthiritis
Dosages-
Osteoarthiritis, musculoskeletal pain- 60mg/day
Primary dysmennorrheoa- 60 to 120mg/day
Rheumatoid arthiritis- 90mg/day
Gouty arthiritis, acute pain associated with dental surgery- 120mg/day
Pharmacology/ Pharmacokinetics:
Pharmacology-
Etorcoxib is a selective inhibitor of COX-2. The COX-1 isoenzyme is constitutely expressed in most tissues and is
particularly invloved prostaglandin snthesis in the kidneys, platelets and gastric mucosa, products of of COX-1
appear cytoprotective and inhibition of this isoform has been associated with antiplatelet activity and gastrointestinal
toxicity. On the other hand the inhibition of of COX-2y etoricoxib is responsible for its analgesic and anti-inflammatory
and its low incidence of adverse effects.
Pharmacokinetics-
Etoricoxib is rapidly absorbed with a mean bioavailability of approximately 100%. Food does not significantly affect
absorption. Etoricoxib undergoes extensive metabolism by the hepatic cytochrome enzymes, mostly by the
CYP 450 3A4
It has an elimnation half-life of aproximately 22 hours and a plasma clearance of 3 litres/hour. Most of the drug is
eliminated by the kidneys and a part is eliminated through the faeces.
Interaction with Food:
Food does not significantly affect absorption.
Pregnancy and lactation:
Preganancy and lactation- caution to be excercised
